Heidelberg Pharma AG (XTER:HPHA) Margin of Safety % (DCF FCF Based) : N/A (As of Jun. 16, 2024)

View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Heidelberg Pharma AG's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Heidelberg Pharma AG's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Heidelberg Pharma AG's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Heidelberg Pharma AG's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's Margin of Safety % (DCF FCF Based) falls into.

Heidelberg Pharma AG Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Heidelberg Pharma AG (XTER:HPHA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

HPHA:Germany HPHA:Germany HPHA:Germany

Address

Gregor-Mendel-Street 22, Ladenburg, DEU, 68526

Website

https://www.heidelberg-pharma.com

Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

Executives

Prof. Dr. Andreas Pahl

Board of Directors

Heidelberg Pharma AG (XTER:HPHA) Headlines

No Headlines